Loading
A phase 2 trial of Envafolimab, Lenvatinib in endometrial cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer is a phase 2 interventional study registered as NCT05112991 by 3D Medicines (Sichuan) Co., Ltd., with 108 participants planned, started 2022-03-04 and due to reach its primary completion in 2026-12. Interventions recorded: Envafolimab+Lenvatinib, Envafolimab. Conditions listed: Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 3D Medicines, Envafolimab, Lenvatinib, Anti-angiogenic therapy.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Envafolimab, Lenvatinib, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/